Medication Possession Ratio vs. Proportion of Days Covered

Onco360 recommends that we track compliance and persistency for each drug individually since they have unique frequencies of administration

Inqovi Approved for the Treatment of MDS

Inqovi® Now Approved for the Treatment of Myelodysplastic Syndromes by Dr. David Schoenbaechler, PharmD, BCOP, CSP Dr. Joseph Barone, PharmD, BCOP Inqovi is a combination of...

Tazverik Approved for New Indications

Tazverik (tazemetostat) indicated for the treatment of adults and pediatric patients aged 16 years and older for Both Epithelioid Sarcoma and Follicular Lymphoma

Cutaneous Squamous Cell Carcinoma

Basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC) are categorized as non-melanoma skin cancers (NMSCs).

Epithelioid Sarcoma

Epithelioid sarcoma (ES) is a rare, slow-growing subtype of STS that accounts for approximately 1% of all STS cases annually.

Chronic Myeloid Leukemia Overview

Chronic Myeloid Leukemia (CML) is a slowly progressing cancer of the blood and bone marrow, which is characterized by the presence of the Philadelphia chromosome

Onco360 Selected to Dispense Inrebic

Onco360®, the nation’s largest independent Oncology Pharmacy, announced today that it was selected to be a specialty pharmacy network partner for Celgene’s new product Inrebic® (fedratinib)